Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the ...

Medical experts discuss whether GLP-1 medications, including Mounjaro and Zepbound, could become comprehensive treatments for ...

USA: Researchers have reported a potential risk of severe hypercalcemia when tirzepatide, a dual GIP and GLP-1 receptor ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

WHO added 20 adult and 15 child medicines to its essential list * Cancer immunotherapies and GLP-1 diabetes drugs now ...

Scientists have developed a new 4-in-1 weight loss drug combining GLP-1, GIP, glucagon, and PYY hormones, aiming to match bariatric surgery-level results while reducing obesity-related risks like ...

The World Health Organization has added key GLP-1 drugs, semaglutide and tirzepatide, to its Essential Medicines List for ...

Scientists have created a pre-clinical weight loss drug combining GLP-1, GIP, glucagon and peptide YY hormones to match ...

– Hengrui to present six abstracts highlighting clinical progress of GLP-1/GIP dual receptor agonist HRS9531 (KAI-9531) and GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes and obesity – ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...

Over the last four years, weight-loss drugs that dampen down appetite and promote satiety have revolutionised obesity ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including ...